DSC Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

DSC Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-69,000	Closed	-$10.8M	–	93
2020 Q4	$10.8M	Hold	69,000	–	–	8.91%	5
2020 Q3	$7.9M	Buy	69,000 +26,500	+62%	+$2.86M	5.28%	5
2020 Q2	$4.77M	Sell	42,500 -2,500	-6%	-$265K	5.23%	8
2020 Q1	$4.04M	Sell	45,000 -23,500	-34%	-$2.31M	3.95%	9
2019 Q4	$7.41M	Buy	68,500 +16,000	+30%	+$1.71M	3.55%	12
2019 Q3	$5.14M	Buy	52,500 +7,500	+17%	+$845K	1.02%	18
2019 Q2	$5.89M	Hold	45,000	–	–	1.04%	19
2019 Q1	$6.08M	Sell	45,000 -10,000	-18%	-$1.24M	1.12%	16
2018 Q4	$5.36M	Buy	+55,000	New	+$6.5M	0.65%	17

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DSC Advisors's ALXN Position: Q1 2021 in Review

DSC Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 69,000 shares — an estimated $10.8M sold.

DSC Advisors first reported a position in ALXN in Q4 2018 and held it in 9 quarters. The position peaked at $10.8M in Q4 2020. 752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

DSC Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
DSC Advisors sold 69,000 Alexion Pharmaceuticals shares in Q1 2021, an estimated $10.8M.
DSC Advisors first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 9 quarters.
DSC Advisors's Alexion Pharmaceuticals position peaked at $10.8M in Q4 2020.
752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on DSC Advisors's 13F filing for Q1 2021, filed 14 May 2021.